The global intravenous (IV) ibuprofen market size reached USD 7.8 Billion in 2025. The analyst expects the market to reach USD 13.6 Billion by 2034, exhibiting a growth rate (CAGR) of 6.20% during 2026-2034.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth.
Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.
Ibuprofen belongs to the nonsteroidal anti-inflammatory drug (NSAID) class used to treat inflammation, pain, and fever. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is used alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the body's production of certain natural substances that cause inflammation. It helps to reduce narcotic analgesic requirements and lower pain levels with an excellent safety profile. IV ibuprofen also aids in improving pain control and reducing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.
Intravenous (IV) Ibuprofen Market Trends:
The steadily rising geriatric population and the increasing prevalence of arthritis, cardiovascular diseases (CVDs), and cancer across the globe are creating a positive outlook for the market. In line with this, the widespread product adoption to manage and treat inflammatory diseases, rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, and osteoarthritis is favoring the market growth. Moreover, hectic working schedules and unhealthy lifestyles, along with a consequent decline in physical activity and proper nutrition, have led to a rise in the incidences of chronic diseases, which is acting as another growth-inducing factor.Apart from this, the increasing product utilization to treat mild fever, dental pain, gastrointestinal pain, and ductus arteriosus in pediatrics is providing an impetus to the market growth. Moreover, IV ibuprofen is employed to relieve muscle or rheumatic pain, backache, neuralgia, sprains, strains, sports injuries, and musculoskeletal diseases, which is facilitating the market growth.
Furthermore, the increasing demand for IV ibuprofen in orthopedic patients post knee or hip replacement surgeries to reduce pain and morphine use is positively influencing the market growth. Other factors, including significant improvements in the healthcare infrastructure, growing health consciousness among individuals, and the rising expenditure capacities of consumers, are anticipated to drive the market growth.
Key Market Segmentation:
The research provides an analysis of the key trends in each sub-segment of the global intravenous (IV) ibuprofen market report, along with forecasts at the global, regional and country level from 2026-2034. The report has categorized the market based on product dose, indication and age group.Breakup by Product Dose:
- 100 Mg Dose
- 200 Mg Dose
- 400 Mg Dose
- 800 Mg Dos.
Breakup by Indication:
- Pain/Inflammatory
- Feve.
Breakup by Age Group:
- Pediatrics
- Adult.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Afric.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.Key Questions Answered in This Report
- What was the size of the global Intravenous (IV) ibuprofen market in 2025?
- What is the expected growth rate of the global Intravenous (IV) ibuprofen market during 2026-2034?
- What are the key factors driving the global Intravenous (IV) ibuprofen market?
- What has been the impact of COVID-19 on the global Intravenous (IV) ibuprofen market?
- What is the breakup of the global Intravenous (IV) ibuprofen market based on the indication?
- What is the breakup of the global Intravenous (IV) ibuprofen market based on the age group?
- What are the key regions in the global Intravenous (IV) ibuprofen market?
- Who are the key players/companies in the global Intravenous (IV) ibuprofen market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Intravenous (IV) Ibuprofen Market
6 Market Breakup by Product Dose
7 Market Breakup by Indication
8 Market Breakup by Age Group
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Cumberland Pharmaceuticals Inc.
- Hyloris Pharmaceuticals SA
- Recordati Rare Diseases Inc.
- VALMOR Laboratories CA
- Xgen Pharmaceuticals Djb Inc.
